Indefinite Delivery Contract SPE2DU25D8002

Award Date 7/1/25
Last Date to Order 3/6/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The federal contract IDV award is for an Indefinite Delivery Contract (IDC) from the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Cardinal Health, Inc. as the prime contractor. The contract has a ceiling value of $4,999,999.00 and a period of performance from July 1, 2025 to March 6, 2036. The contract is part of the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) procurement, which aims to establish multiple Prime Vendor Contracts to provide...
The federal contract IDV award is a Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contract issued by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain. The single-award IDV is valued at up to $999,999,999 and has a period of performance from July 1, 2025 to March 6, 2036. The prime contractor is Cardinal Health, Inc., a global healthcare services and products company. The contract aims to establish Prime Vendor Contracts to provide worldwide...
The federal contract IDV award to Cardinal Health, Inc. is for a Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contract, valued at up to $999,999,999.00, with the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain as the funding agency. This single-award, indefinite delivery contract is intended to provide worldwide pharmaceutical support, including brand, generic, and specialty pharmaceuticals, to the Department of Defense (DoD), United States Coast Guard,...
The federal contract IDV award to Cardinal Health, Inc. is a single-award Indefinite Delivery Contract (IDC) valued at $76,117,431.74 with a period of performance from March 7, 2025, to March 6, 2035. The contract is with the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain, a defense agency, to provide pharmaceutical (brand, generic, specialty) and pharmaceutical-related products worldwide to the Department of Defense (DoD), United States Coast Guard, and other designated...
This is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Cardinal Health, Inc. to provide pharmaceutical prime vendor support to the Department of Defense (DoD), United States Coast Guard, and other designated government customers. The contract has a 30-month base period and three 30-month option periods, with a total estimated value of $30.3 billion. The purpose of the contract is to establish a Pharmaceutical...
The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain has awarded an Indefinite Delivery Contract (IDC) with a total ceiling value of $4,999,999.00 to Cardinal Health, Inc. for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contract. This single-award IDC, with a period of performance from July 1, 2025 to March 6, 2036, aims to establish prime vendor contracts for providing worldwide pharmaceutical support, including brand, generic, and specialty drugs,...
The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain has awarded an Indefinite Delivery Contract (IDC) to Cardinal Health, Inc. for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency (DHA), United States Coast Guard, and US Naval Fleet. The $4,999,999.00 single-award IDC has a 30-month base period and three 30-month option...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to Cardinal Health, Inc., a global healthcare services and products company, to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency (DHA), U.S. Coast Guard, and U.S. Naval Fleet. The single-award IDC has a $4,999,999.00 ceiling value and a 30-month base period with three 30-month option periods, for a total estimated value of $30.3...
The subject indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Cardinal Health, Inc., a global healthcare services and products company, to provide pharmaceutical support to various Department of Defense (DoD) customers worldwide. The single-award IDC has a 30-month base period and three 30-month option periods, with a total estimated value of $4,999,999.00. The contract aims to establish a Pharmaceutical Prime Vendor Global...
The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain has awarded an Indefinite Delivery Contract (IDC) to Cardinal Health, Inc. for the provision of pharmaceutical and related medical products. The contract, valued at up to $4,999,999, is a single-award IDC with a base period of 30 months and three 30-month option periods, for a total potential period of performance through March 2036. The IDC is part of the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V)...

The federal contract IDV award is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Cardinal Health, Inc. as the prime contractor. The IDC, valued at $4,999,999.00, is for the provision of pharmaceutical, medical, and radiopharmaceutical products to support the Department of Defense (DoD), United States Coast Guard, and other government agencies globally.

The contract aims to establish a Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) to provide worldwide pharmaceutical support, including normal day-to-day operations, planned and unplanned contingencies, Prime Vendor Readiness, and War Readiness Materiel. The program will cover medical pharmaceuticals in the 6505 stock catalog/schedule and the current National Drug Code (NDC) database, with separate distribution fees for brand/generic and specialty drugs. The contract has a 30-month base period and three 30-month option periods, for a total estimated value of $30.3 billion across multiple regional awards. This will be an unrestricted, fully competitive acquisition, with the intention to have at least three different contractors awarded.

Generated 6/6/25, 9:50 AM